【2h】

Does Body Fat Mass Define Survival in Patients Starting Peritoneal Dialysis?

机译:身体脂肪量是否会影响腹膜透析患者的生存?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

♦ Background and Aims: Peritoneal dialysis (PD) is characterized by a gain in fat mass. Unlike subcutaneous fat, visceral fat is associated with metabolic syndrome and survival. We prospectively examined whether visceral or subcutaneous fat could predict outcome in patients undergoing PD.♦ Methods: We studied 117 new patients (57 men) undergoing PD between February 2006 and November 2011. Baseline body composition was measured on computed tomograms. Visceral obesity was defined as a visceral fat area exceeding 100 cm2, and subcutaneous obesity, as a subcutaneous fat area exceeding 130 cm2.♦ Results: Among the 117 patients, 37 and 29 were diagnosed with visceral and subcutaneous obesity respectively. Visceral and subcutaneous obesity were both present in 21 patients. In the study population, the 1-year and 5-year survival rates were 94% and 59%. The rates of peritonitis and exit-infection were 0.31 and 0.14 episodes per patient-year. Mortality was greater in patients with visceral obesity than in those without visceral obesity (p = 0.005). Visceral obesity had no influence on peritonitis and exit-infection rates. Subcutaneous obesity was associated neither with survival nor with peritonitis or exit-site infection. In a multivariate Cox regression analysis, visceral obesity was not a risk factor for poor outcome.♦ Conclusions: Increased visceral fat at PD initiation is not an independent predictor of poor survival. Any impact of visceral or subcutaneous fat mass on outcomes in patients undergoing PD would be better defined by larger, long-term studies.
机译:♦背景和目的:腹膜透析(PD)的特点是脂肪量增加。与皮下脂肪不同,内脏脂肪与代谢综合征和生存有关。我们前瞻性地检查了内脏脂肪或皮下脂肪是否可以预测PD患者的结局。♦方法:我们研究了2006年2月至2011年11月间117例接受PD的新患者(57名男性)。通过计算机体层摄影术测量基线身体成分。内脏肥胖定义为内脏脂肪面积超过100 cm 2 ,皮下肥胖定义为皮下脂肪面积超过130 cm 2 。♦结果:在117例患者中, 37名和29名分别被诊断为内脏和皮下肥胖。内脏型和皮下型肥胖均存在于21例患者中。在研究人群中,1年和5年生存率分别为94%和59%。腹膜炎和出口感染的发生率每患者年为0.31和0.14次。内脏型肥胖患者的死亡率高于无内脏型肥胖患者(p = 0.005)。内脏肥胖对腹膜炎和出口感染率没有影响。皮下肥胖与生存,腹膜炎或出口部位感染均无关。在多因素Cox回归分析中,内脏肥胖不是不良结局的危险因素。♦结论:PD开始时内脏脂肪增加并不是生存不良的独立预测因素。较大的长期研究可以更好地确定内脏或皮下脂肪量对PD患者结局的任何影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号